CD274 and melanoma: NCT03554083 is studying the effect of combined treatment with cobimetinib (MEK inhibitor) and atezolizumab (PD-L1-Ab), and with vemurafenib (BRAF inhibitor), cobimetinib, and atezolizumab for the treatment of patients with high-risk stage III melanoma [38].